These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
680 related articles for article (PubMed ID: 26839356)
1. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study. Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771 [TBL] [Abstract][Full Text] [Related]
4. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study. Liao L; Tang J; Hong Z; Jiang W; Li Y; Kong L; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Yu J; Yang W; Pan Z; Ding PR BMC Cancer; 2024 Feb; 24(1):164. PubMed ID: 38302968 [TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022 [TBL] [Abstract][Full Text] [Related]
6. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609 [TBL] [Abstract][Full Text] [Related]
7. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557 [TBL] [Abstract][Full Text] [Related]
8. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea. Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187 [TBL] [Abstract][Full Text] [Related]
9. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186 [TBL] [Abstract][Full Text] [Related]
10. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?]. Zaanan A; Taieb J Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656 [TBL] [Abstract][Full Text] [Related]
12. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812 [TBL] [Abstract][Full Text] [Related]
15. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. Chouhan H; Sammour T; Thomas ML; Moore JW J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198 [TBL] [Abstract][Full Text] [Related]
16. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335 [TBL] [Abstract][Full Text] [Related]
17. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis. Ejaz A; Casadaban L; Maker AV J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636 [TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. Sanoff HK; Carpenter WR; Martin CF; Sargent DJ; Meyerhardt JA; Stürmer T; Fine JP; Weeks J; Niland J; Kahn KL; Schymura MJ; Schrag D J Natl Cancer Inst; 2012 Feb; 104(3):211-27. PubMed ID: 22266473 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P; Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730 [No Abstract] [Full Text] [Related]
20. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients. Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]